Kyverna Therapeutics (NASDAQ:KYTX) versus OKYO Pharma (NASDAQ:OKYO) Head to Head Contrast

OKYO Pharma (NASDAQ:OKYO) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Insider & Institutional Ownership

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares OKYO Pharma and Kyverna Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Kyverna Therapeutics	N/A	-51.12%	-37.91%

Earnings and Valuation

This table compares OKYO Pharma and Kyverna Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A
Kyverna Therapeutics	$7.03 million	12.17	-$60.37 million	($3.47)	-0.57

OKYO Pharma has higher earnings, but lower revenue than Kyverna Therapeutics.

Risk and Volatility

OKYO Pharma has a beta of -0.32, indicating that its share price is 132% less volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for OKYO Pharma and Kyverna Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	0	0	1	0	3.00
Kyverna Therapeutics	0	1	5	1	3.00

OKYO Pharma currently has a consensus price target of $7.00, indicating a potential upside of 514.04%. Kyverna Therapeutics has a consensus price target of $18.33, indicating a potential upside of 825.93%. Given Kyverna Therapeutics’ higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than OKYO Pharma.

Summary

Kyverna Therapeutics beats OKYO Pharma on 6 of the 10 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.